Education
About Us
Working with TipRanks
Follow Us
Viridian Therapeutics (VRDN)
NASDAQ:VRDN
VRDN Stock Chart & Stats
$32.93
-$0.90(-4.30%)
At close: 4:00 PM EST
$32.93
-$0.90(-4.30%)
Day’s Range― - ―
52-Week Range$9.90 - $34.29
Previous CloseN/A
Volume201.32K
Average Volume (3M)814.59K
Market Cap
$3.16B
Enterprise Value$2.54B
Total Cash (Recent Filing)$490.90M
Total Debt (Recent Filing)$23.82M
Price to Earnings (P/E)―
Beta1.29
Next Earnings
Mar 05, 2026EPS Estimate
-0.98Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-0.34
Shares Outstanding95,442,010
10 Day Avg. Volume1,087,693
30 Day Avg. Volume814,586
Financial Highlights & Ratios
PEG Ratio0.19
Price to Book (P/B)1.94
Price to Sales (P/S)4309.19
P/FCF Ratio-5.59
Enterprise Value/Market Cap0.80
Enterprise Value/Revenue35.85
Enterprise Value/Gross Profit35.85
Enterprise Value/Ebitda-8.49
Forecast
1Y Price Target
$44.50Price Target Upside35.14% Upside
Rating ConsensusStrong Buy
Number of Analyst Covering13
EPS Forecast (FY)N/A
Revenue Forecast (FY)N/A
Bulls Say, Bears Say
Bulls Say
Clinical Efficacy And DifferentiationPhase III data showing veligrotug met primary and secondary endpoints with faster onset, meaningful diplopia benefit and fewer or shorter infusions versus the standard therapy supports a persuasive clinical differentiation story for uptake.
Market Expansion Via Subcutaneous At-home TherapyA self-administered subcutaneous candidate designed for at-home use could broaden the treatable patient population and capture share from intravenous therapy by offering greater convenience and simpler dosing.
Regulatory ReviewFDA granting Priority Review for veligrotug shortens the regulatory timeline and signals the agency views the therapy as a meaningful improvement, potentially enabling quicker market access if approved.
Bears Say
Clinical Trial And Execution RiskClinical trial and execution risks, including the potential for disappointing readouts or operational setbacks, could derail anticipated program milestones and reduce expected upside.
Concentration Of Late-stage Program RiskHeavy reliance on a small number of pivotal programs leaves the company sensitive to single-study failures or delays, which could materially impact near-term prospects.
Regulatory UncertaintyRegulatory uncertainty remains and an unfavorable approval decision or unexpected regulatory requirements could lead to meaningful downside to valuation.
Viridian Therapeutics News
VRDN FAQ
What was Viridian Therapeutics’s price range in the past 12 months?
Viridian Therapeutics lowest stock price was $9.90 and its highest was $34.29 in the past 12 months.
What is Viridian Therapeutics’s market cap?
Viridian Therapeutics’s market cap is $3.16B.
When is Viridian Therapeutics’s upcoming earnings report date?
Viridian Therapeutics’s upcoming earnings report date is Mar 05, 2026 which is in 37 days.
How were Viridian Therapeutics’s earnings last quarter?
Viridian Therapeutics released its earnings results on Nov 05, 2025. The company reported -$0.34 earnings per share for the quarter, beating the consensus estimate of -$1.019 by $0.679.
Is Viridian Therapeutics overvalued?
According to Wall Street analysts Viridian Therapeutics’s price is currently Undervalued.
Does Viridian Therapeutics pay dividends?
Viridian Therapeutics does not currently pay dividends.
What is Viridian Therapeutics’s EPS estimate?
Viridian Therapeutics’s EPS estimate is -0.98.
How many shares outstanding does Viridian Therapeutics have?
Viridian Therapeutics has 95,442,010 shares outstanding.
What happened to Viridian Therapeutics’s price movement after its last earnings report?
Viridian Therapeutics reported an EPS of -$0.34 in its last earnings report, beating expectations of -$1.019. Following the earnings report the stock price went up 8.293%.
Which hedge fund is a major shareholder of Viridian Therapeutics?
Currently, no hedge funds are holding shares in VRDN
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Viridian Therapeutics Stock Smart Score
Outperform
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Strong Buy
Average Price Target:
$44.50 (35.14% Upside)
$44.50 (35.14% Upside)
Hedge Fund Trend
Increased
By 1.6M Shares
Last Quarter.
Last Quarter.
Insider Transactions
Bought Shares
Worth $10.0M over
the Last 3 Months
the Last 3 Months
Crowd Wisdom
Very Positive
Last 7 Days ▲ 2.8%
Last 30 Days ▲ 9.7%
Last 30 Days ▲ 9.7%
Technicals
SMA
Positive
20 days / 200 days
Momentum
-3.56%
12-Months-Change
Fundamentals
Return on Equity
-47.40%
Trailing 12-Months
Asset Growth
-0.57%
Trailing 12-Months
Company Description
Viridian Therapeutics
Viridian Therapeutics, Inc., a biotechnology company, develops treatments for patients suffering from serious diseases. It develops VRDN-001, a humanized monoclonal anti-IGF-1R antibody that is in Phase 1/2 clinical trial for the treatment of thyroid eye disease (TED); VRDN-002, an IGF-1R antibody, which is in Phase 1 clinical trial; and VRDN-003, a therapeutic antibody targeting IGF-1R for the treatment of TED. The company was formerly known as Miragen Therapeutics, Inc. and changed its name to Viridian Therapeutics, Inc. in January 2021. Viridian Therapeutics, Inc. was founded in 2006 and is headquartered in Waltham, Massachusetts.
VRDN Stock 12 Month Forecast
Average Price Target
$44.50
▲(35.14% Upside)
Technical Analysis
Dianthus Therapeutics
―
Pharvaris
―
Edgewise Therapeutics
―
Janux Therapeutics Inc
―
Biohaven Ltd.
―
Ownership Overview
4.13% Insiders
24.60% Mutual Funds
0.38% Other Institutional Investors
58.83% Public Companies and Individual Investors